Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248532 | 1.00 | PTGS2 (1.00) | PTGS2MAPK14 | |
| SCHEMBL6351573 | 0.90 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL6350326 | 0.90 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL6342283 | 0.87 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL6344630 | 0.87 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL6341013 | 0.86 | PTGS2 (1.00) | PTGS2MAPK14 | |
| SCHEMBL6354448 | 0.86 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL6342907 | 0.86 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL7042862 | 0.85 | MAPK14 (0.81) | PTGS2MAPK14 | |
| SCHEMBL8304225 | 0.84 | PTGS2 (0.78) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-0778834-B1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2000-01-26 | — | — | EP | claimed |
| EP-0915848-A1 | 1,2-DIARYLINDOLE AS COX-2 INHIBITORS | LABORATOIRES UPSA (FR) | 1999-05-19 | — | — | EP | claimed |
| WO-1998005639-A1 | 1,2-DIARYLINDOLE AS COX-2 INHIBITORS | LABORATOIRES UPSA (FR) | 1998-02-12 | — | — | WO | claimed |
| EP-0778834-A1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1997-06-18 | — | — | EP | claimed |
| WO-1996006840-A1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1996-03-07 | — | — | WO | claimed |
| EP-1039914-A4 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RES FOUNDATION INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1146789-A4 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6960611-B2 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | INSTITUTE OF MATERIA MEDICA (CN) | 2005-11-01 | — | — | US | disclosed |
| US-20040058977-A1 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | INSTITUTE OF MATERIA MEDIC, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2004-03-25 | — | — | US | disclosed |
| EP-1109553-A4 | TREATING INFLAMMATORY DISEASES OF THE HEAD AND NECK WITH CYCLOOXYGENASE-2 INHIBITORS | CORNELL RES FOUNDATION INC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| EP-0778834-B1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999030721-A1 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0915848-A1 | 1,2-DIARYLINDOLE AS COX-2 INHIBITORS | LABORATOIRES UPSA (FR) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998005639-A1 | 1,2-DIARYLINDOLE AS COX-2 INHIBITORS | LABORATOIRES UPSA (FR) | 1998-02-12 | — | — | WO | disclosed |
| EP-0778834-A1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1997-06-18 | — | — | EP | disclosed |
| US-5521213-A | NONSTEROID ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-05-28 | — | — | US | disclosed |
| WO-1996006840-A1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058977-A1 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885MAPK14 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.